细胞程序性死亡蛋白5与宫颈癌患者病理特征的关系及对淋巴结转移发生风险的评估价值

doi:10.3969/j.issn.1006-5725.2023.24.011

Abstract

Abstract:

Objective To explore the expression of programmed cell death protein 5 in cervical cancer and its relationship with lymph node metastasis. Methods 98 cases of cervical cancer patients admitted to our hospital were selected as the observation group， and 98 cases of cervical benign lesions were selected as the control group. The expression levels of PDCD5 in serum and lesion tissues of the two groups were compared to analyze the relationship between PDCD5 and pathological features of cervical cancer， and the diagnostic value of PDCD5 in lymph node metastasis of patients with cervical cancer was analyzed by ROC curve. Results The expression levels of PDCD5 in serum and lesion tissue of observation group were lower than those of control group （P < 0.05）. With the increase of clinical stage and pathological grade of cervical cancer， the expression of PDCD5 in serum and lesion tissue was significantly decreased （P < 0.05）. Among the 98 patients with cervical cancer， 32 had lymph node metastasis. The expression levels of PDCD5 in serum and lesion tissue of lymph node metastasis group were lower than those of non-lymph node metastasis group （P < 0.05）. ROC curve results showed that the AUCs of PDCD5 in serum and lesion tissue to predict lymph node metastasis of cervical cancer patients were 0.810 and 0.850， respectively， with no statistical significance （P > 0.05）. Conclusion The Programmed cell death protein 5 is closely related to the pathological features of patients with cervical cancer，and it has a good predictive effect on lymph node metastasis，which is worthy of further study and application.

Key words: cervical cancer, programmed cell death protein 5, clinical stage, pathological grade, lymph node metastasis

CLC Number:

R711.74

Guang YANG,Danfeng ZHANG,Xiaona FENG,Yan. ZHANG. Expression of programmed cell death protein 5 in cervical cancer and its relationship with lymph node metastasis[J]. The Journal of Practical Medicine, 2023, 39(24): 3210-3213.

Figures/Tables 5

Tab.1

Tab.2

Tab.3

Tab.4

Fig.1

References 21

1	张涛红，张萌，高丽，等. 经手术治疗宫颈癌患者的临床特征研究［J］. 中国全科医学，2020，23（25）：3207-3211.
2	杨杨，梁罗娇，周琛斐，等. CAⅨ联合CD8⁺TIL对宫颈癌淋巴结转移的预测价值［J］. 实用医学杂志，2021，37（12）：1549-1553.
3	TAKEDA T， KOMATSU M， CHIWAKI F，et al. Upregulation of IGF2R evades lysosomal dysfunction-induced apoptosis of cervical cancer cells via transport of cathepsins［J］. Cell Death Dis， 2019， 10（12）： 876.
4	徐霄鸾，逄越，苏鹏. 细胞程序性死亡因子家族分子在细胞凋亡中的调控作用［J］. 中国生物化学与分子生物学报，2020，36（3）：244-251.
5	任安立，李靖凯，周冬冬. 程序化细胞死亡因子5对缺氧／复氧诱导的心肌细胞凋亡和自噬的影响及机制［J］. 中国病理生理杂志，2017，33（2）：251-256.
6	刘晓冬，司亚丽，洪丹妮. 程序性细胞死亡因子5在子宫内膜癌患者中的表达分析［J］. 中国性科学，2020，29（9）：23-26.
7	卢霞，许旭. SIRT1调控Nrf2信号通路对宫颈癌细胞增殖、凋亡及迁移侵袭的影响［J］. 中国计划生育和妇产科，2021，13（6）：39-44.
8	WANG J， WU Y， LI Y，et al. Guanosine monophosphate synthase upregulation mediates cervical cancer progression by inhibiting the apoptosis of cervical cancer cells via the Stat3/P53 pathway［J］. Int J Oncol，2021，58（4）：30-33.
9	李萍，王帆，魏欣. 鼻窦鳞状细胞癌组织中PRL-3和C-erbB-2和PDCD5的表达及与病理特征的关系［J］. 中国肿瘤临床与康复，2020，27（10）：1199-1202.
10	王雷，沈维高，刘艳波，等. 过表达程序性细胞死亡基因5提高脑神经胶质瘤细胞对替莫唑胺的化疗敏感性［J］.中国肿瘤生物治疗杂志，2019，26（8）：868-875.
11	LU J， JIANG Z， CHEN Y， et al. Knockout of programmed cell death 5 （PDCD5） gene attenuates neuron injury after middle cerebral artery occlusion in mice［J］. Brain Res， 2016， 1650：152-161.
12	杨丰赫，叶菁菁，郑铭. 程序性细胞死亡分子5（PDCD5）研究进展［J］. 生理科学进展，2021，52（1）：1-6.
13	KWAK S， LEE S H， HAN E J，et al. Serine/threonine kinase 31 promotes PDCD5-mediated apoptosis in p53-dependent human colon cancer cells［J］. J Cell Physiol，2019，234（3）：2649-2658.
14	MA Z， GUO D， WANG Q，et al. Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma［J］. Theranostics，2019，9（10）：2967-2983.
15	刘秀芬，敖洪峰，敖金平. 程序化细胞死亡分子5在乳腺癌组织中的表达及其临床意义［J］. 检验医学，2021，36（11）：1151-1158.
16	KE Y， ABOODY M S， Alturaiki W， et al. Photosynthesized gold nanoparticles from Catharanthus roseus induces caspase-mediated apoptosis in cervical cancer cells （HeLa）［J］. Artif Cells Nanomed Biotechnol，2019，47（1）：1938-1946.
17	LIN M H， YU T A， CHANG C，et al. NMR resonance assignments of the programmed cell death protein 5 （PDCD5） from Toxoplasma gondii［J］. Bio NMR Assi，2020，14（2）：277-280.
18	许学宗，刘培培，金博，等. 血清ANXA2、PDCD5及COL4A3表达水平与肺癌患者临床病理特征及肿瘤转移的相关性［J］. 热带医学杂志，2021，21（2）：205-208.
19	GAO F， ZHAO M， HUANG S，et al. Clinicopathological Significance of Decreased Expression of the Tumor Inhibitor Gene PDCD5 in Osteoclastoma［J］. Genet Test Mol Bioma，2019，23（11）：807-814.
20	ZHANG K， WANG J， ZHANG S，et al. Effects of Tumor Necrosis Factor Alpha on the Expression of Programmed Cell Death Factor 5 in Arthritis［J］. Orthop Surg，2019，11（4）：698-704.
21	PARK S Y， HONG J Y， LEE S Y，et al. Club cell-specific role of programmed cell death 5 in pulmonary fibrosis［J］. Nat Commun.，2021，12（1）：1-13.

组别	例数	血清PDCD5（ng/mL）	病灶组织中PDCD5
对照组	98	1.54 ± 0.49	0.38 ± 0.025
观察组	98	0.76 ± 0.26	0.27 ± 0.018
t值		13.920	35.349
P值		< 0.001	< 0.001

分期	例数	血清PDCD5（ng/mL）	病灶组织中PDCD5
Ⅰ期	30	1.23 ± 0.37	0.31 ± 0.021
Ⅱ期	36	0.75 ± 0.24	0.25 ± 0.016
Ⅲ期	32	0.51 ± 0.16	0.20 ± 0.012
F值		58.112	339.931
P值		< 0.001	< 0.001

分级	例数	血清PDCD5（ng/mL）	病灶组织中PDCD5
G1	33	1.32 ± 0.46	0.30 ± 0.019
G2	34	0.77 ± 0.21	0.26 ± 0.015
G3	31	0.49 ± 0.13	0.19 ± 0.010
F值		62.535	426.494
P值		< 0.001	< 0.001

组别	例数	血清PDCD5 （ng/mL）	病灶组织中PDCD5
非淋巴结转移组	66	1.27 ± 0.42	0.29 ± 0.019
淋巴结转移组	32	0.41 ± 0.11	0.18 ± 0.016
t值		11.368	28.235
P值		< 0.001	< 0.001

[1]	Jianliang YAN,Zeyu XIE,Rongrong JING,Ming. CUI. Research on establishing gastric cancer lymph node metastasis prediction model based on machine learning and routine laboratory indicators [J]. The Journal of Practical Medicine, 2024, 40(6): 844-849.
[2]	Jing HU,Xu WANG,Xiaoqin GONG,Rui LING,Tao YOU,Chunhua DAI,Ye TIAN,Fei. CHEN. Analysis of dosimetric parameters of acute radiation enteritis in cervical cancer patients treated with concurrent chemoradiotherapy [J]. The Journal of Practical Medicine, 2024, 40(5): 672-676.
[3]	Baoni JIANG,Meiqin ZHANG,Lu YANG,Zhiyuan CHEN,Na′na HAN. Application and prospects of ctDNA detection in HPV associated cervical cancer [J]. The Journal of Practical Medicine, 2024, 40(2): 129-132.
[4]	Ping LI,Tuo TANG,Aixue ZHENG,Luping ZHANG,Tao WANG,Xian HONG,Zhihui DENG. Generation of MCM2 gene inducible knockout cervical cancer HeLa cells and its effect on DNA replication [J]. The Journal of Practical Medicine, 2024, 40(2): 133-139.
[5]	Shenglong YUAN,Huanhuan HU,Zhen GONG. Efficacy of the ACS NSQIP surgical risk calculator in open radical hysterectomy [J]. The Journal of Practical Medicine, 2024, 40(2): 140-145.
[6]	Min WANG,Dan MU,Dejun KONG,Li YANG,Lu YE,Dan HE. HPV16 E6 regulates miR-23a expression and promotes invasion and migration of cervical cancer cells [J]. The Journal of Practical Medicine, 2024, 40(2): 146-152.
[7]	Fei CHEN,Xiaoqin GONG,Yunpeng YU,Tao YOU,Xu WANG,Chunhua DAI,Jing HU. Feasibility of automatic segmentation of CTV and OARs in postoperative radiotherapy for cervical cancer using AccuLearning [J]. The Journal of Practical Medicine, 2024, 40(2): 153-157.
[8]	Yongzhen ZHANG,Shanshan WANG,Hailing ZHAO,Liwei. XU. Levels and clinical significance of serum miR-651 and miR-630 in patients with cervical cancer [J]. The Journal of Practical Medicine, 2024, 40(2): 158-162.
[9]	Pixi WEI,Yu DENG,Cailing ZHAO,Liu XU,Min ZHANG. The expression of WDR5 in cervical cancer tissue and its relationship with clinical and pathological characteristics of patients [J]. The Journal of Practical Medicine, 2024, 40(2): 169-173.
[10]	Qingwei ZHANG,Rutie. YIN. Hotspots and advances on diagnosis and treatment for cervical cancer [J]. The Journal of Practical Medicine, 2024, 40(17): 2357-2362.
[11]	ZHONG Hua, ZENG Meiqing, ZHOU Yuting, HE Shunqing, LU Binghui.. Transfection of human cervical cancer cell HeLa by ultrasound microbubble contrast agent carrying pcD⁃ NA⁃STC1 [J]. The Journal of Practical Medicine, 2023, 39(8): 936-943.
[12]	LU Yanyue, ZHAO Xinxin, LIU Liyan, WANG Kai, YE Jingwen, LIU Lingyun, WANG Baojin.. Effect and mechanism of endogenous aromatic ligand ITE on the biological behavior of cervical cancer cells [J]. The Journal of Practical Medicine, 2023, 39(6): 679-687.
[13]	Huaming ZHANG,Wanshan HE,Yun HAN,Guanqiao CHEN,Bin CHEN,Zhifu WEI,Hengying WU,Bin. WEN. Screening of gene differential expression of adenosine deaminase RNA specific 1 in cervical cancer cells based on transcriptome sequencing technology [J]. The Journal of Practical Medicine, 2023, 39(24): 3169-3174.
[14]	Peipei LIN,Xiaodong ZHOU,Wei. SONG. Prediction value of tumor volume to uterine volume ratio combined with tumor ADC value in pathological grading of endometrial carcinoma [J]. The Journal of Practical Medicine, 2023, 39(23): 3071-3075.
[15]	Xiran SHI,Heng WANG,Libing HE,Zhiqiang QIU,Hongjian LI,Xiaoxue. XU. Advance in predicting lymph node metastasis of breast cancer by multimodal MRI [J]. The Journal of Practical Medicine, 2023, 39(22): 2861-2865.

Expression of programmed cell death protein 5 in cervical cancer and its relationship with lymph node metastasis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 21

Related Articles 15

Recommended Articles

Metrics

Comments